NASDAQ · DTIL
Precision BioSciences, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for DTIL: Nov 03, 2026
Precision BioSciences, Inc. Common Stock is expected to report earnings on 11/03/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.02. The reported EPS for the same quarter last year was $-1.84.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.02 | $-0.85 | $-1.19 | 2 |
| Dec 2026 | $-1.23 | $-1.20 | $-1.26 | 2 |
| Mar 2027 | $-0.39 | $-0.39 | $-0.39 | 1 |
| Jun 2027 | $-0.40 | $-0.40 | $-0.40 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · RTTNews · Zacks- BNK Invest · Oct 6, 4:43 PM EDTPrecision Biosciences is Now Oversold (DTIL)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- RTTNews · Aug 24, 6:53 AM EDTPrecision BioSciences Doses First Patient In Phase 1/2 Of PBGENE-DMD In Duchenne Muscular Dystrophy(RTTNews) – Precision BioSciences, Inc. (DTIL), a clinical-stage gene editing company, announced the dosing of the first patient in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD).
- RTTNews · Aug 20, 1:34 PM EDTPrecision BioSciences Posts Q2 Loss; PBGENE-HBV Delivers Clinical CccDNA Elimination Data(RTTNews) – Precision BioSciences, Inc. (DTIL), a clinical-stage gene editing company, recently reported second-quarter 2026 financial results and provided business updates, highlighted by the first clinical biopsy evidence of direct cccDNA elimination with PBGENE-HBV.
- Zacks · Jul 8, 10:32 AM EDTStrength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength?Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- RTTNews · May 27, 3:53 AM EDTPrecision BioSciences Shows First Evidence Of CccDNA Elimination In Hepatitis B Patients; Stock Up(RTTNews) – Precision BioSciences, Inc. (DTIL) has unveiled landmark clinical data from its ELIMINATE-B study, showing for the first time that a therapeutic agent can directly eliminate and inactivate cccDNA— the root source of hepatitis B viral replication— in patient liver biop
- Zacks · May 5, 8:25 AM EDTPrecision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue EstimatesPrecision BioSciences (DTIL) delivered earnings and revenue surprises of -25.93% and +40.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 4, 5:50 PM EDTNuvation Bio Inc. (NUVB) Lags Q1 Earnings EstimatesNuvation Bio (NUVB) delivered earnings and revenue surprises of -91.30% and +0.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Apr 27, 8:18 AM EDTAnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- Zacks · Apr 20, 7:59 AM EDTCartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?Cartesian Therapeutics, Inc. (RNAC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- Zacks · Apr 14, 9:55 AM EDTShould You Buy Precision BioSciences (DTIL) After Golden Cross?When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
- Zacks · Mar 12, 8:15 AM EDTPrecision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue EstimatesPrecision BioSciences (DTIL) delivered earnings and revenue surprises of +271.43% and +178.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Mar 9, 5:35 PM EDTCoherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue EstimatesCoherus Oncology (CHRS) delivered earnings and revenue surprises of -9.68% and -2.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Precision BioSciences, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.